Johnson & Johnson (NYSE: JNJ) announces the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers, where patients continue to face significant unmet need.
Read the full article: Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation //
Source: https://www.businesswire.com/news/home/20260729714290/en/Johnson-Johnson-Completes-Acquisition-of-Firefly-Bio-Inc.-to-Advance-Next-Generation-Oncology-Innovation